Vanda Pharmaceuticals (NASDAQ:VNDA) Stock Keeps Buy Rating at HC Wainwright

Vanda Pharmaceuticals (NASDAQ:VNDA)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a report released on Monday, MarketBeat Ratings reports. They currently have a $20.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price target suggests a potential upside of 338.40% from the company’s current price.

VNDA has been the topic of a number of other research reports. B. Riley Financial reiterated a “buy” rating and issued a $12.00 price target (down from $17.00) on shares of Vanda Pharmaceuticals in a research note on Monday, August 10th. Oppenheimer assumed coverage on shares of Vanda Pharmaceuticals in a research note on Wednesday, September 23rd. They issued an “outperform” rating and a $10.00 price target on the stock. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a research note on Friday, July 17th. Six investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Vanda Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $13.08.

Vanda Pharmaceuticals Stock Up 0.9%

Vanda Pharmaceuticals stock traded up $0.04 during mid-day trading on Monday, reaching $4.56. The stock had a trading volume of 618,301 shares, compared to its average volume of 1,530,071. The company has a market capitalization of $275.83 million, a price-to-earnings ratio of -0.99 and a beta of 0.69. The company has a 50-day moving average price of $5.16 and a two-hundred day moving average price of $5.97. Vanda Pharmaceuticals has a one year low of $4.27 and a one year high of $9.94. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.61 and a quick ratio of 1.60.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings results on Wednesday, August 5th. The biopharmaceutical company reported ($1.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.46). The firm had revenue of $50.53 million during the quarter, compared to the consensus estimate of $61.93 million. Vanda Pharmaceuticals had a negative return on equity of 49.81% and a negative net margin of 127.41%. On average, analysts expect that Vanda Pharmaceuticals will post -3.02 EPS for the current fiscal year.

Hedge Funds Weigh In On Vanda Pharmaceuticals

Institutional investors have recently made changes to their positions in the business. BlackRock Inc. bought a new position in shares of Vanda Pharmaceuticals in the 2nd quarter worth approximately $46,841,000. Renaissance Technologies LLC lifted its stake in shares of Vanda Pharmaceuticals by 11.2% in the 1st quarter. Renaissance Technologies LLC now owns 3,759,559 shares of the biopharmaceutical company’s stock worth $25,979,000 after purchasing an additional 378,598 shares during the period. State Street Corp lifted its stake in shares of Vanda Pharmaceuticals by 16.6% in the 2nd quarter. State Street Corp now owns 3,516,405 shares of the biopharmaceutical company’s stock worth $21,520,000 after purchasing an additional 500,843 shares during the period. AIGH Capital Management LLC lifted its stake in shares of Vanda Pharmaceuticals by 37.6% in the 1st quarter. AIGH Capital Management LLC now owns 2,750,000 shares of the biopharmaceutical company’s stock worth $19,002,000 after purchasing an additional 751,569 shares during the period. Finally, Quantinno Capital Management LP lifted its stake in shares of Vanda Pharmaceuticals by 25.0% in the 1st quarter. Quantinno Capital Management LP now owns 327,193 shares of the biopharmaceutical company’s stock worth $2,261,000 after purchasing an additional 65,391 shares during the period. Institutional investors own 88.14% of the company’s stock.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing therapies for disorders of the central nervous system. The company was founded in 2003 and is headquartered in Washington, DC Its work centers on conditions involving sleep, circadian rhythms, and psychiatric health.

Vanda’s commercial products include Hetlioz (tasimelteon), a melatonin receptor agonist approved in the United States for Non-24-Hour Sleep-Wake Disorder and Smith-Magenis Syndrome, and Fanapt (iloperidone), an atypical antipsychotic used to treat schizophrenia in adults.